Introduction: we investigated efficacy and safety of a brief chemo-immunotherapy RFND followed by randomization between R maintenance or observation in a study specifically devised for elderly. Material and methods: From January 2004 to December 2007, 235 pts (age 60-75) with untreated advanced stage FL were enrolled and treated with: 4 courses of RFND (Fludarabine, Mitoxantrone, Dexamethasone) followed by 4 weekly R consolidation; CR+CRu+PR pts were randomized between R maintenance (375 mg/m 2 every months for 4 doses) or observation. PCR analysis for IgH/Bcl-2 rearrangement was performed on bone marrow (BM) at diagnosis, after RFND, R consolidation and during maintenance/observation. Preliminary analysis was done after the first 80 randomized pts. This analysis included 95 pts recruited within this time frame. Results: Median age 65 (60-75); stage III/IV 16/70%; FLIPI low(L) 10%, intermediate(I) 30%, high(H) 60%. PCR analysis was done in 91 pts at diagnosis: 56% were Bcl-2+. N ORR CR PCR negativity associated with CR(46 pts Bcl2+ evaluable) Baseline 95 – – – R-FND x 4 95 86 (90%) 51 (54%) 18 (39%) R consolidation 88 80 (84%) 68 (72%) 31 (67%) Univariate analysis was performed: high CR rate was achieved also in poor prognosis pts (CR according to FLIPI: L 75%, I 88%, H 81%). The most frequent CTC grade 3-4 toxicity was neutropenia in 25% of the courses, with only 6 serious infections. No toxic deaths occurred. Any grade R related reactions were seen in 9% of the courses with R discontinuation in only 2 pts. So far 91 pts are alive and 4 died of lymphoma. Conclusions: A brief chemo-immunotherapy RFND + R consolidation is safe and effective with a high CR rate and PCR negativity in elderly pts with untreated FL with FLIPI H. R consolidation convirted in CR 56% of PR after RFND. The whole study will provide insights on the role of R maintenance after R-chemotherapy

Elderly patients with untreated advanced stage follicular lymphoma (FL) treated with brief chemoimmunotherapy Rituximab (R) FND+/-rituximab maintenance: Preliminary analysis of a prospective randomized study / U., Vitolo; M., Ladetto; C., Boccomini; E., Gamba; L., Baldini; M., Ceccarelli; A., Chiappella; A., De Renzo; F., Di Raimondo; A., Gallamini; B., Mantoan; Martelli, Maurizio; I., Alvarez; G., Parvis; M., Petrini; A., Pinto; S., Pozzi; Pulsoni, Alessandro; L., Rigacci; A., Tucci; F., Zaja; E., Gallo. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 19 (SUPPL. 4):(2008), pp. 182-182. (Intervento presentato al convegno 10th International Conference on Malignant Lymphoma tenutosi a Lugano, SWITZERLAND nel JUN 04-07, 2008) [10.1093/annonc/mdn245].

Elderly patients with untreated advanced stage follicular lymphoma (FL) treated with brief chemoimmunotherapy Rituximab (R) FND+/-rituximab maintenance: Preliminary analysis of a prospective randomized study

MARTELLI, Maurizio;PULSONI, Alessandro;
2008

Abstract

Introduction: we investigated efficacy and safety of a brief chemo-immunotherapy RFND followed by randomization between R maintenance or observation in a study specifically devised for elderly. Material and methods: From January 2004 to December 2007, 235 pts (age 60-75) with untreated advanced stage FL were enrolled and treated with: 4 courses of RFND (Fludarabine, Mitoxantrone, Dexamethasone) followed by 4 weekly R consolidation; CR+CRu+PR pts were randomized between R maintenance (375 mg/m 2 every months for 4 doses) or observation. PCR analysis for IgH/Bcl-2 rearrangement was performed on bone marrow (BM) at diagnosis, after RFND, R consolidation and during maintenance/observation. Preliminary analysis was done after the first 80 randomized pts. This analysis included 95 pts recruited within this time frame. Results: Median age 65 (60-75); stage III/IV 16/70%; FLIPI low(L) 10%, intermediate(I) 30%, high(H) 60%. PCR analysis was done in 91 pts at diagnosis: 56% were Bcl-2+. N ORR CR PCR negativity associated with CR(46 pts Bcl2+ evaluable) Baseline 95 – – – R-FND x 4 95 86 (90%) 51 (54%) 18 (39%) R consolidation 88 80 (84%) 68 (72%) 31 (67%) Univariate analysis was performed: high CR rate was achieved also in poor prognosis pts (CR according to FLIPI: L 75%, I 88%, H 81%). The most frequent CTC grade 3-4 toxicity was neutropenia in 25% of the courses, with only 6 serious infections. No toxic deaths occurred. Any grade R related reactions were seen in 9% of the courses with R discontinuation in only 2 pts. So far 91 pts are alive and 4 died of lymphoma. Conclusions: A brief chemo-immunotherapy RFND + R consolidation is safe and effective with a high CR rate and PCR negativity in elderly pts with untreated FL with FLIPI H. R consolidation convirted in CR 56% of PR after RFND. The whole study will provide insights on the role of R maintenance after R-chemotherapy
2008
10th International Conference on Malignant Lymphoma
04 Pubblicazione in atti di convegno::04d Abstract in atti di convegno
Elderly patients with untreated advanced stage follicular lymphoma (FL) treated with brief chemoimmunotherapy Rituximab (R) FND+/-rituximab maintenance: Preliminary analysis of a prospective randomized study / U., Vitolo; M., Ladetto; C., Boccomini; E., Gamba; L., Baldini; M., Ceccarelli; A., Chiappella; A., De Renzo; F., Di Raimondo; A., Gallamini; B., Mantoan; Martelli, Maurizio; I., Alvarez; G., Parvis; M., Petrini; A., Pinto; S., Pozzi; Pulsoni, Alessandro; L., Rigacci; A., Tucci; F., Zaja; E., Gallo. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 19 (SUPPL. 4):(2008), pp. 182-182. (Intervento presentato al convegno 10th International Conference on Malignant Lymphoma tenutosi a Lugano, SWITZERLAND nel JUN 04-07, 2008) [10.1093/annonc/mdn245].
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/485111
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact